Standard Biotools Inc.

Industrials
Biotechnology: Laboratory Analytical Instruments
www.standardbio.com

Moat Score
Safety Score

Market Cap $629.89M
PE -4
Debt $110.13M
Cash $211.94M
EV $528.08M
FCF -$148.51M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$170.60M
EBIT	-$124.45M
ROE	-35%
ROA	-18%
FCF	-$148.51M
Equity	$489.33M
Growth Stability	1
PE	-3.69
PB	1.29
P/FCF	-4.24
P/S	4.04
Price/Cash	0.34
Debt/Equity	0.23
Debt/FCF	-0.74
Net Margins	-118%
Gross Margins	49%
Op. Margins	-80%
Sales Growth YoY	77%
Sales Growth QoQ	21%
Sales CAGR	2%
Equity CAGR	5%
Earnings Growth YoY	28%

Earnings Growth QoQ	-41%
Sales CAGR 5Y	-1%
Equity CAGR 5Y	11%
Earnings CAGR 3Y	5%
Sales CAGR 3Y	5%
Equity CAGR 3Y	54%
Market Cap	$629.89M
Revenue	$155.90M
Assets	$681.54M
Total Debt	$110.13M
Cash	$211.94M
Shares Outstanding	346.09M
EV	528.08M
Moat Score	2%
Safety Score	65%
Working Capital	332.99M
Current Ratio	3.76
Gross Profit	$75.71M
Shares Growth 3y	8%
Equity Growth QoQ	-4%
Equity Growth YoY	-471%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Standard BioTools Inc. develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines. Its segments include Proteomics and Genomics. Proteomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of proteins. Genomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of genes and their functions. It provides insights in health and disease using its mass cytometry and microfluidics technologies, which serve applications in proteomics and genomic. It works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories around the world, focusing on the needs in translational and clinical research, including oncology, immunology, and immunotherapy. The Company distributes its systems through its direct sales force and support organizations.

SEC Filings

Direct access to Standard Biotools Inc. (LAB) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Standard Biotools Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Standard Biotools Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Standard Biotools Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Standard Biotools Inc..

Years

Calculation mode

= -$1.5B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$149M	-$149M	-$149M	-$149M	-$149M	-$149M	-$149M	-$149M	-$149M	-$149M	-$149M	-$1.5B
DCF		-$135M	-$123M	-$112M	-$101M	-$92M	-$84M	-$76M	-$69M	-$63M	-$57M	-$573M
Value	-$1.5B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-45%	-46%	-73%	-59%	-52%	-55%	-38%	-45%	-194%	-70%	-118%
ROA	-	-13%	-24%	-20%	-16%	-20%	-16%	-23%	-30%	-23%	-18%
ROE	-	-46%	-143%	-196%	-82%	-42%	-38%	-63%	233%	50%	-35%

Bad Net Margins (-118.1%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-5.06	-4.41	-7.61	-6.73	-1.43	-1.93	-0.94	-0.7	-2.56	-0.74
Debt over Equity	1.3	1.7	3.66	6.31	2.39	0.35	0.39	0.57	-0.8	-0.8	0.23
Growth Stability	-	-	-	-	-	-	-	-	-	-	1

Good Debt/FCF ratio (-0.74)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (0.23)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-1%	-9%	-2%	11%	4%	18%	-5%	-25%	9%	-1%
Earnings YoY growth	-	1%	43%	-20%	-3%	10%	-18%	12%	221%	-61%	-
Equity YoY growth	-	-24%	-54%	-42%	133%	113%	-9%	-32%	-186%	82%	11%
FCF YoY growth	-	29%	14%	-42%	-0%	48%	-25%	104%	63%	-51%	-